Brief: Lansen Pharmaceutical unit enters asset purchase agreement with Novartis
31/03/2014 24:58
March 30 (Reuters) - Lansen Pharmaceutical Holdings Ltd 0503.HK : * Subsidiary of the company, entered into asset purchase agreement with Novartis * Subsidiary of the company, entered into licence agreement to grant the licences, relating to the pharmaceutical product * Deal for total cash consideration comprising upfront payment of $8 million, plus additional milestone payments of a maximum $1.5 million * Source text for Eikon ID:nHKS7d38Z4 ((For more news, please click here 0503.HK )) ((Bangalore Newsroom; +91 806749 1130))
Recent news on Lansen Pharmaceutical Holdings
See all newsBrief: Lansen Pharmaceutical Says Stock Exchange Approved Withdrawal Of Listing Of Shares From 9 AM, 19 Dec
Brief: Lansen Pharmaceutical Updates Withdrawal Of Listing Of Shares On Stock Exchange
Brief: Lansen Pharmaceutical Says Trading In Shares Will Be Halted
Brief: Lansen Pharmaceutical Posts FY Revenue Of $65.6 Mln VS $54.2 Mln
Brief: Lansen Pharmaceutical Sees Net Profit Attributable Of Approximately $8.1 Million For Year